Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk


1 Department of Laboratory Medicine and Pathology, and Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America, 2 Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, United States of America, 3 Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, 4 Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America, 5 Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Quebec and Laval University, Quebec City, Canada, 6 Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, United States of America, 7 Genetics Department, Queensland Institute of Medical Research, Brisbane, Australia, 8 Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon–Centre Léon Bérard, Lyon, France, 9 INSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France, 10 Department of Molecular Pharmacology and Experimental Therapeutics (MPET), Mayo Clinic, Rochester, Minnesota, United States of America, 11 Centre d’Innovation Genôme Québec et Université McGill, Montreal, Canada, 12 Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, The Netherlands, 13 Institut Curie, Department of Tumour Biology, Paris, France, 14 Institut Curie, INSERM U830, Paris, France, 15 Université Paris Descartes, Sorbonne Paris Cité, Paris, France, 16 Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland, 17 Kathleen Cunningham Consortium for Research into Familial Breast Cancer–Peter MacCallum Cancer Center, Melbourne, Australia, 18 Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy, 19 FOM, Fondazione Istituto FIRC di Oncologia Molecolare, Milan, Italy, 20 Centre de Familial Breast and Ovarian Cancer, Department of Gynaecology and Obstetrics and Centre for Integrated Oncology (CIO). Center for Molecular Medicine Cologne (CMMC), University Hospital of Cologne, Cologne, Germany, 21 Department of Oncology, Lund University, Lund, Sweden, 22 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America, 23 Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, New York, United States of America, 24 Department of Obstetrics and Gynecology, and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria, 25 Sheba Medical Center, Tel Aviv, Israel, 26 Department of Clinical Genetics, Odense University Hospital, Odense, Denmark, 27 Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Canada, 28 Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 29 Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, California, United States of America, 30 Center for Translational Cancer Research, Department of Biological Sciences, University of Delaware, Newark, Delaware, United States of America, 31 Genetic Counseling Unit, Hereditary Cancer Program, IDIBELL–Catalan Institute of Oncology, Barcelona, Spain, 32 Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, United States of America, 33 Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America, 34 Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America, 35 Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida, United States of America, 36 Clinical Cancer Genetics (for the City of Hope Clinical Cancer Genetics Community Research Network), City of Hope, Duarte, California, United States of America, 37 Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto (IOV–IRCCS), Padova, Italy, 38 Department of Molecular Genetics, National Institute of Genetics, Hungary, 39 Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, 40 Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, United States of America, 41 Molecular Diagnostics Laboratory, IRPP, National Centre for Scientific Research Demokritos, Aghia Paraskevi Attikis, Athens, Greece, 42 Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah, United States of America, 43 Molecular Oncology Laboratory, Hospital Clinic San Carlos, IDISSC, Madrid, Spain, 44 Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland, 45 Human Genetics Group, Spanish National Cancer Centre (CNIO), and Biomedi cal Network on Rare Diseases (CIBERER), Madrid, Spain, 46 Department of Epidemiology, Columbia University, New York, New York, United States of America, 47 Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States of America, 48 Department of Genetics, University of Pretoria, Pretoria, South Africa, 49 Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany, 50 Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America, 51 Division of Human Cancer Genetics, Departments of Internal Medicine and Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, United States of America, 52 Section of Genetic Oncology, Department of Laboratory Medicine, University of Pisa and University Hospital of Pisa, Pisa, Italy, 53 Center for Clinical Cancer Genetics and Global Health, University of Chicago Medical Center, Chicago, Illinois, United States of America, 54 Department of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America, 55 Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium, 56 Departments of Medicine, Epidemiology, and Biostatistics, University of California San Francisco, San Francisco, California, United States of America, 57 Genetic Epidemiology Laboratory, Department of Pathology, University of Melbourne, Parkville, Australia, 58 N. N. Petrov Institute of Oncology, St. Petersburg, Russia, 59 Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill University, Montreal, Quebec, Canada, 60 Vilnius University Hospital Santariskiu Clinics, Hematology, Oncology and Transfusion Medicine Center, Department of Molecular and Regenerative Medicine, Vilnius, Lithuania, 61 Department of Epidemiology, Cancer Prevention Institute of California, Fremont, California, United States of America, 62 The Hong Kong Hereditary Breast Cancer Family Registry, Cancer Genetics Center, Hong Kong Sanatorium and Hospital, Hong Kong, China, 63 Oncogenetics Laboratory, University Hospital Vall d’Hebron and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, 64 Department of Medical Oncology, University Hospital Vall d’Hebron, Barcelona, Spain, 65 Department of Pathology, Landspitali University Hospital and BMC, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, 66 Department of Breast Medical Oncology and Clinical Cancer Genetics, University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America, 67 Clalit National Israeli Cancer Control Center and Department of Community Medicine and Epidemiology, Carmel
Novel Modifiers of BRCA1 Cancer Risk

Abstract

BRCA1-associated breast and ovarian cancer risks can be modified by common genetic variants. To identify further cancer risk-modifying loci, we performed a multi-stage GWAS of 11,705 BRCA1 carriers (of whom 5,920 were diagnosed with breast and 1,839 were diagnosed with ovarian cancer), with a further replication in an additional sample of 2,646 BRCA1 carriers. We identified a novel breast cancer risk modifier locus at 1q32 for BRCA1 carriers (rs2290854, P = 2.7 × 10^{-6}; HR = 1.14, 95% CI: 1.09–1.20). In addition, we identified two novel ovarian cancer risk modifier loci: 17q21.31 (rs17631303, P = 1.4 × 10^{-9}; HR = 1.27, 95% CI: 1.17–1.38) and 4q32.3 (rs4691139, P = 3.4 × 10^{-9}; HR = 1.20, 95% CI: 1.17–1.38). The 4q32.3 locus was not associated with ovarian cancer risk in the general population or BRCA2 carriers, suggesting a BRCA1-specific association. The 17q21.31 locus was also associated with ovarian cancer risk in 8,211 BRCA2 carriers (P = 2.0 × 10^{-8}). These loci may lead to improved understanding of the etiology of breast and ovarian cancers in BRCA1 carriers. Based on the joint distribution of the known BRCA1 breast cancer risk-modifying loci, we estimated that the breast cancer lifetime risks for the 5% of BRCA1 carriers at lowest risk are 28%–50% compared to 81%–100% for the 5% at highest risk. Similarly, based on the known ovarian cancer risk-modifying loci, the 5% of BRCA1 carriers at lowest risk have an estimated lifetime risk of developing ovarian cancer of 28% or lower, whereas the 5% at highest risk will have a risk of 63% or higher. Such differences in risk may have important implications for risk prediction and clinical management for BRCA1 carriers.


Editor: Kent W. Hunter, National Cancer Institute, United States of America

Received September 7, 2012; Accepted November 14, 2012; Published March 27, 2013

Copyright: © 2013 Couch et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: The study was supported by NIH grant CA128978, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a U.S. Department of Defense Ovarian Cancer Idea award (W81XWH-10-1-0341), grants from the Breast Cancer Research Foundation and the Komen Foundation for the Cure; Cancer Research UK grants C12292/A1174 and C1278/A10118; the European Commission’s Seventh Framework Programme grant agreement 223175 (HEALTH-F2-2009-223175). Breast Cancer Family Registry Studies (BCFR): supported by the National Cancer Institute, National Institutes of Health under RFA # CA-06-003 and through cooperative agreements with members of the Breast Cancer Family Registry (BCFR) and Principal Investigators, including Cancer Care Ontario (U01 CA69467), Cancer Prevention Institute of California (U01 CA64917), Columbia University (U01 CA69398), Fox Chase Cancer Center (U01 CA69631), Huntsman Cancer Institute (U01 CA69446), and University of Melbourne (U01 CA69638). The Australian BCFR was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia), and the Victorian Breast Cancer Research Consortium. Melissa C. Southey is a NHMRC Senior Research Fellow and a Victorian Breast Cancer Research Consortium Group Leader. Carriers at FCCC were also identified with support from National Institutes of Health grants P01 CA16094 and R01 CA22435. The New York BCFR was also supported by National Institutes of Health grants P01 CA13696 and P30 ES00908. The Utah BCFR was also supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH grant U01 RR025764, and by Award Number P30 CA24014 from the National Cancer Institute. Baltic Familial Breast Ovarian Cancer Consortium (BFBOCC): BFBOCC is partly supported by Lithuania (BFBOCC-LT), Research Council of Lithuania grant LIG-19/2010, and Hereditary Cancer Association (Paveldimo vežio asociacija). Latvia (BFBOCC-LV) is partly supported by LSC grant 10.0010.08. The study was supported by NIH grant CA128978, an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA116201), a U.S. Department of Defense Ovarian Cancer Idea award (W81XWH-10-1-0341), grants from the Breast Cancer Research Foundation and the Komen Foundation for the Cure; Cancer Research UK grants C12292/A1174 and C1278/A10118; the European Commission’s Seventh Framework Programme grant agreement 223175 (HEALTH-F2-2009-223175).

Keywords: BRCA1; breast cancer; ovarian cancer; GWAS; multi-stage analysis; breast cancer risk modifier; ovarian cancer risk modifier; BRCA carriers; genetic modifier.
Introduction

Breast and ovarian cancer risk estimates for BRCA1 mutation carriers vary by the degree of family history of the disease, suggesting that other genetic factors modify cancer risks for this population [1–4]. Studies by the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) have shown that a subset of common alleles influencing breast and ovarian cancer risk in the general population are also associated with breast cancer risk in BRCA1 mutation carriers [5–11]. In particular, the breast cancer associations were limited to loci associated with estrogen receptor (ER)-negative breast cancer in the general population (6q25.1, 12p11 and TOX3) [8–11]. To systematically search for loci associated with breast or ovarian cancer risk for BRCA1 carriers we previously conducted a two-stage genome-wide association study (GWAS) [12]. The initial stage involved analysis of 555,616 SNPs in 2383 BRCA1 mutation carriers (1,193 unaffected and 1,190 affected). After replication testing of 89 SNPs showing the strongest association, with 5,986 BRCA1 mutation carriers, a locus on 19p13 was shown to be associated with breast cancer risk for BRCA1 mutation carriers. The same locus was also associated with the risk of estrogen-receptor (ER) negative and triple negative (ER, Progesterone and HER2 negative) breast cancer in the general population [12,13]. The Collaborative Oncogene Environment Study (COGS) consortium recently developed a 211,155 SNP custom genotyping array (iCOGS) in order to provide cost-effective genotyping of common and rare genetic variants to identify novel loci that explain the residual genetic variance of breast, ovarian and HER2 negative breast cancer in the general population [12,13].

Novel Modifiers of BRCA1 Cancer Risk

Professorship. German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC): The German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) is supported by the German Cancer Aid (grant no 109076, Rita K. Schmutzler) and by the Center for Molecular Medicine Cologne (CMMC). Genetic Modifiers of cancer risk in BRCA1/2 mutation carriers (GEMO): The GEMO study was supported by the French National Cancer Institute (Inserm, UMR 8001, BCH), the Foundation for Economic Development, Innovation and Export (FEDIE), and the Novartis Foundation for Vaccine Development and Global Health (FNDV). The GEMO study was supported by the UK National Cancer Research Institute (NCRI) and by the Ralph and Marion Falk Medical Research Trust, the Entertainment Industry Fund National Women’s Cancer Research Institute (NAROD): NAROD was supported by NIH grant: 1R01 CA149429-01. National Cancer Institute (NCI): Drs. Mark H. Greene and Phuong L. Mai were supported by the Intramural Research Program of the US National Cancer Institute (NCI) and by support services contracts NO2-CP-11019-50 and N02-CP-65504 with Westat, Rockville, MD. National Israeli Cancer Control Center (NICCC): NICCC is supported by the Queensland Cancer Fund; the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia; and the Cancer Foundation of Western Australia. Amanda B. Spurdle is an NHMRC Senior Research Fellow. The Clinical Follow Up Study was funded from 2001–2009 by NHMRC and currently by the National Breast and Ovarian Cancer Foundation and Cancer Australia (CA128787). The Guangzhou Cancer Institute (GCI) is supported by the Guangzhou Cancer Hospital and the Guangdong Provincial Health Bureau. The Center for Molecular Medicine Cologne (CMMC): CMMC is supported by the DFG, the Centre for Genetic Analysis (CGA), and by EU. Lyons Cancer Centre (LYC): Lyons Cancer Centre was supported by the Cancer Research UK (C07680/A19845, C07812/A17500, C09380/A18793, C10354/A18877, C11230/A20515, C13298/A19845), Cancer Research UK Foundation, the French National Cancer Institute (Inserm, UMR 8001, BCH), the Foundation for Economic Development, Innovation and Export (FEDIE), and the Novartis Foundation for Vaccine Development and Global Health (FNDV). The French National Cancer Institute (Inserm, UMR 8001, BCH), the Foundation for Economic Development, Innovation and Export (FEDIE), and the Novartis Foundation for Vaccine Development and Global Health (FNDV). The United Kingdom Familial Ovarian Cancer Registries (UKFOCR): UKFOCR was supported by a project grant from CRUK to Paul Pharoah. University of Pennsylvania (UPENN): The UPENN study was supported by the Intramural Research Program of the US National Cancer Institute (NCI) and by support services contracts NO2-CP-11019-50 and N02-CP-65504 with Westat, Rockville, MD. National Israeli Cancer Control Center (NICCC): NICCC is supported by the Queensland Cancer Fund; the Cancer Councils of New South Wales, Victoria, Tasmania, and South Australia; and the Cancer Foundation of Western Australia. Amanda B. Spurdle is an NHMRC Senior Research Fellow. The Clinical Follow Up Study was funded from 2001–2009 by NHMRC and currently by the National Breast and Ovarian Cancer Foundation and Cancer Australia (CA128787). The Guangzhou Cancer Institute (GCI) is supported by the Guangzhou Cancer Hospital and the Guangdong Provincial Health Bureau. The Center for Molecular Medicine Cologne (CMMC): CMMC is supported by the DFG, the Centre for Genetic Analysis (CGA), and by EU. Lyons Cancer Centre (LYC): Lyons Cancer Centre was supported by the Cancer Research UK (C07680/A19845, C07812/A17500, C09380/A18793, C10354/A18877, C11230/A20515, C13298/A19845), Cancer Research UK Foundation, the French National Cancer Institute (Inserm, UMR 8001, BCH), the Foundation for Economic Development, Innovation and Export (FEDIE), and the Novartis Foundation for Vaccine Development and Global Health (FNDV). The Australian Breast Cancer Family Registry (ABCFR): ABCFR was supported by the Queensland Cancer Fund (QCCF), Department of Health and Ageing, Australian Government, Cancer Research Australia, and the Cancer Council Queensland. The Australian Breast Cancer Family Registry (ABCFR): ABCFR was supported by the Queensland Cancer Fund (QCCF), Department of Health and Ageing, Australian Government, Cancer Research Australia, and the Cancer Council Queensland. The breast cancer associations were limited to loci associated with estrogen receptor (ER)-negative breast cancer in the general population (6q25.1, 12p11 and TOX3) [8–11]. To systematically search for loci associated with breast or ovarian cancer risk for BRCA1 carriers we previously conducted a two-stage genome-wide association study (GWAS) [12]. The initial stage involved analysis of 555,616 SNPs in 2383 BRCA1 mutation carriers (1,193 unaffected and 1,190 affected). After replication testing of 89 SNPs showing the strongest association, with 5,986 BRCA1 mutation carriers, a locus on 19p13 was shown to be associated with breast cancer risk for BRCA1 mutation carriers. The same locus was also associated with the risk of estrogen-receptor (ER) negative and triple negative (ER, Progesterone and HER2 negative) breast cancer in the general population [12,13]. The Collaborative Oncogene Environment Study (COGS) consortium recently developed a 211,155 SNP custom genotyping array (iCOGS) in order to provide cost-effective genotyping of common and rare genetic variants to identify novel loci that explain the residual genetic variance of breast, ovarian

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: couch.fergus@mayo.edu (Fergus J Couch); Antonis@srl.cam.ac.uk (Antonis C Antoniou)

† These authors contributed equally to this work.
**Author Summary**

BRCA1 mutation carriers have increased and variable risks of breast and ovarian cancer. To identify modifiers of breast and ovarian cancer risk in this population, a multi-stage GWAS of 14,351 BRCA1 mutation carriers was performed. Loci 1q32 and TCF7L2 at 1q25.3 were associated with breast cancer risk, and two loci at 4q32.2 and 17q21.31 were associated with ovarian cancer risk. The 4q32.3 ovarian cancer locus was not associated with ovarian cancer risk in the general population or in BRCA2 carriers and is the first indication of a BRCA1-specific risk locus for either breast or ovarian cancer. Furthermore, modeling the influence of these modifiers on cumulative risk of breast and ovarian cancer in BRCA1 mutation carriers for the first time showed that a wide range of individual absolute risks of each cancer can be estimated. These differences suggest that genetic risk modifiers may be incorporated into the clinical management of BRCA1 mutation carriers.

and prostate cancers and fine-map known susceptibility loci. A total of 32,557 SNPs on the iCOGS array were selected on the basis of the BRCA1 GWAS for the purpose of identifying breast and ovarian cancer risk modifiers for BRCA1 mutation carriers. Genotype data from the iCOGS array were obtained for 11,705 samples from BRCA1 carriers and the 17 most promising SNPs were then genotyped in an additional 2,646 BRCA1 carriers. In this manuscript we report on the novel risk modifier loci identified by this multi-stage GWAS. No study has previously shown how the absolute risks of breast and ovarian cancer for BRCA1 mutation carriers vary by the combined effects of risk modifying loci. Here we use the results from this study, in combination with previously identified modifiers, to obtain absolute risks of developing breast and ovarian cancer for BRCA1 mutation carriers based on the joint distribution of all known genetic risk modifiers.

**Materials and Methods**

**Ethics statement**

All carriers participated in clinical or research studies at the host institutions, approved by local ethics committees.

**Study subjects**

BRCA1 mutation carriers were recruited by 45 study centers in 25 countries through CIMBA. The majority were recruited through cancer genetics clinics, and enrolled into national or regional studies. The remainder were identified by population-based sampling or community recruitment. Eligibility for CIMBA association studies was restricted to female carriers of pathogenic BRCA1 mutations age 18 years or older at recruitment. Information collected included year of birth, mutation description, self-reported ethnic ancestry, age at last follow-up, ages at breast or ovarian cancer diagnoses, and age at bilateral prophylactic mastectomy and oophorectomy. Information on tumour characteristics, including ER-status of the breast cancers, was also collected. Related individuals were identified through a unique family identifier. Women were included in the analysis if they carried mutations that were pathogenic according to generally recognized criteria.

**GWAS stage 1 samples.** A total of 2,727 BRCA1 mutation carriers were genotyped on the Illumina Infinium 610K array (Figure 1). Of these 1,426 diagnosed with a first breast cancer under age 40 were considered “affected” in the breast cancer association analysis and 683 diagnosed with an ovarian cancer at any time were considered as “affected” in the ovarian cancer analysis. “Unaffected” in both analyses were over age 35 (Table S1) [12].

**Replication study samples.** All eligible BRCA1 carriers from CIMBA with sufficient DNA were genotyped, including those used in Stage 1. In total, 13,310 samples from 45 centers in 25 countries were genotyped using the iCOGS array (Table S2). Among the 13,310 samples, those that were genotyped in the GWAS stage 1 SNP selection stage are referred to as “stage 1” samples, and the remainder are “stage 2” samples. An additional 2,646 BRCA1 samples “stage 3” were genotyped on an iPLEX Mass Array of 17 SNPs from 12 loci selected after an interim analysis of iCOGS array data and were available for analysis after quality control (QC) (Figure 1). Carriers of pathogenic mutations in BRCA2 were drawn from a parallel GWAS of genetic modifiers for BRCA2 mutation carriers. BRCA2 mutation carriers were recruited from CIMBA through 47 studies which were largely the same as the studies that contributed to the BRCA1 GWAS with similar eligibility criteria. Samples from BRCA2 mutation carriers were also genotyped using the iCOGS array. Details of this experiment are described elsewhere [14]. A total of 8,211 samples were available for analysis after QC.

**iCOGS SNP array**

The iCOGS array was designed in a collaboration among the Breast Cancer Association Consortium (BCAC), Ovarian Cancer Association Consortium (OCAC), the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) and CIMBA. The general aims for designing the iCOGS array were to replicate findings from GWAS for identifying variants associated with breast, ovarian or prostate cancer (including subtypes and SNPs potentially associated with disease outcome), to facilitate fine-mapping of regions of interest, and to genotype “candidate” SNPs of interest within the consortia, including rarer variants. Each consortium was given a share of the array: nominally 25% of the SNPs each for BCAC, PRACTICAL and OCAC; 17.5% for CIMBA; and 7.5% for SNPs of common interest between the consortia. The final design comprised 220,123 SNPs, of which 211,155 were successfully manufactured. A total of 32,557 SNPs on the iCOGS array were selected based on 8 separate analyses of stage 1 of the CIMBA BRCA1 GWAS that included 2,727 BRCA1 mutation carriers [12]. After imputation for all SNPs in HapMap Phase II (CEU) a total of 2,568,349 (imputation r$^2>0.30$) were available for analysis. Markers were evaluated for associations with: (1) breast cancer; (2) ovarian cancer; (3) breast cancer restricted to Class 1 mutations (loss-of-function mutations expected to result in a reduced transcript or protein level due to nonsense-mediated RNA decay); (4) breast cancer restricted to Class 2 mutations (mutations likely to generate stable proteins with potential residual or dominant negative function); (5) breast cancer by tumor ER-status; (6) breast cancer restricted to BRCA1 185delAG mutation carriers; (7) breast cancer restricted to BRCA1 5382insC mutation carriers; and (8) breast cancer by contrasting the genotype distributions in BRCA1 mutation carriers, against the distribution in population-based controls. Analyses (1) and (2) were based on both imputed and observed genotypes, whereas the rest were based on only the observed genotypes. SNPs were ranked according to the 1 d.f. score-test for trend P-value (described below) and selected for inclusion based on nominal proportions of 61.5%, 20%, 2.5%, 2.5%, 2.5%, 2.5%, 0.5%, 0.5% and 10.0% for analyses (1) to (8). SNP duplications were not allowed and SNPs with a pairwise r$^2>0.90$ with a higher-ranking SNP were only allowed (up to a maximum
SNP Selection for iCOGS

BRCA1 GWAS
BRCA1 samples (N) = 2,727
SNPs (N) = 2,568,349

SNPs associated with breast or ovarian cancer risk, Selected SNPs (N) = 32,557

iCOGS Stage
Total SNPs (N) = 201,242

BRCA1 GWAS SNPs (N) = 31,812
BRCA1 samples (N) = 11,705

Stage 1 Samples
N=2,387

Stage 2 Samples
N=9,318

17 most significant SNPs

iPlex Stage – Stage 3

BRCA1 samples (N) =2,646
SNPs (N) = 17

Figure 1. Study design for selection of the SNPs and genotyping of BRCA1 samples. GWAS data from 2,727 BRCA1 mutation carriers were analysed for associations with breast and ovarian cancer risk and 32,557 SNPs were selected for inclusion on the iCOGS array. A total of 11,705 BRCA1 samples (after quality control (QC) checks) were genotyped on the 31,812 BRCA1-GWAS SNPs from the iCOGS array that passed QC. Of these samples, 2,387 had been genotyped at the SNP selection stage and are referred to as “stage 1” samples, whereas 9,318 samples were unique to the iCOGS study (“Stage 2” samples). Next, 17 SNPs that exhibited the most significant associations with breast and ovarian cancer were selected for genotyping in a third stage involving an additional 2,646 BRCA1 samples (after QC).

doi:10.1371/journal.pgen.1003212.g001

of 2) if the P-value for association was <10^-4 for analyses (1) and (2) and <10^-3 for other analyses. SNPs with poor Illumina design scores were replaced by the SNP with the highest r^2 (among SNPs with r^2>0.80 based on HapMap data) that had a good quality design score. The analysis of associations with breast and ovarian cancer risks presented here included all 32,557 SNPs on iCOGS that were selected on the basis of the BRCA1 GWAS.

Genotyping and quality control

iCOGS genotyping. Genotyping was performed at Mayo Clinic. Genotypes for samples genotyped on the iCOGS array were called using Illumina’s GenCall algorithm (Text S1). A total of 13,510 samples were genotyped for 211,155 SNPs. The sample and SNP QC process is summarised in Table S3. Of the 13,510 samples, 578 did not fulfil eligibility criteria based on phenotypic
data and were excluded. A step-wise QC process was applied to the remaining samples and SNPs. Samples were excluded due to inferred gender errors, low call rates (<95%), low or high heterozygosity and sample duplications (cryptic and intended). Of the 211,155 markers genotyped, 9,913 were excluded due to Y-chromosome origin, low call rates (<95%), monomorphic SNPs, or SNPs with Hardy-Weinberg equilibrium (HWE) P<10^-7 under a country-stratified test statistic [15] (Table S8). SNPs that gave discordant genotypes among known sample duplicates were also excluded. Multi-dimensional scaling was used to exclude individuals of non-European ancestry. We selected 37,149 weakly correlated autosomal SNPs (pair-wise r^2<0.10) to compute the genomic kinship between all pairs of BRCA1 carriers, along with 197 HapMap samples (CHB, JPT, YRI and CEU). These were converted to distances and subjected to multidimensional scaling (Figure S1). Using the first two components, we calculated the proportion of European ancestry for each individual [12] and excluded samples with >22% non-European ancestry (Figure S1). A total of 11,705 samples and 201,242 SNPs were available for analysis, including 31,812 SNPs selected by the BRCA1 GWAS. The genotyping cluster plots for all SNPs that demonstrated genome-wide significance level of association or are presented below, were checked manually for quality (Figure S2).

**iPLEX analysis.** The most significant SNPs from 4 loci associated with ovarian cancer and 8 loci associated with breast cancer were selected (17 SNPs in total) for stage 3 genotyping. Genotyping using the iPLEX Mass Array platform was performed at Mayo Clinic. CIMBA QC procedures were applied. Samples that failed for ≥20% of the SNPs were excluded from the analysis. No SNPs failed HWE (P<0.01). The concordance among duplicates was ≥98%. Mutation carriers of self-reported non-European ancestry were excluded. A total of 2,646 BRCA1 samples were eligible for analysis after QC.

**Statistical methods.**

The main analyses were focused on the evaluation of associations between each genotype and breast cancer or ovarian cancer risk separately. Analyses were carried out within a survival analysis framework. In the breast cancer analysis, the phenotype of each individual was defined by age at breast cancer diagnosis or age at last follow-up. Individuals were followed until the age of the first breast cancer diagnosis, ovarian cancer diagnosis, or bilateral prophylactic mastectomy, whichever occurred first; or last observation age. Mutation carriers censored at ovarian cancer diagnosis were considered unaffected. For the ovarian cancer analysis, the primary endpoint was the age at ovarian cancer diagnosis. Mutation carriers were followed until the age of ovarian cancer diagnosis, or risk-reducing salpingo-oophorectomy (RRSO) or age at last observation. In order to maximize the number of ovarian cancer cases, breast cancer was not considered as a censoring event in this analysis, and mutation carriers who developed ovarian cancer after a breast cancer diagnosis were considered as affected in the ovarian cancer analysis.

**Association analysis.** The majority of mutation carriers were sampled through families seen in genetic clinics. The first tested individual in a family is usually someone diagnosed with cancer at a relatively young age. Such study designs tend to lead to an over-sampling of affected individuals, and standard analytical methods like Cox regression may lead to biased estimates of the risk ratios [16,17]. To adjust for this potential bias the data were analyzed within a survival analysis framework, by modeling the retrospective likelihood of the observed genotypes conditional on the disease phenotypes. A detailed description of the retrospective likelihood approach has been published [17,18]. The associations between genotype and breast cancer risk at both stages were assessed using the 1 d.f. score test statistic based on this retrospective likelihood [17,18]. To allow for the non-independence among related individuals, we accounted for the correlation between the genotypes by estimating the kinship coefficient for each pair of individuals using the available genomic data and robust variance estimation based on reported family membership [21]. We chose to present P-values based on the kinship adjusted score test as it utilizes the degree of relationship between individuals. A genome-wide level of significance of 5x10^-8 was used [22]. These analyses were performed in R using the GenABEL [23] libraries and custom-written functions in FORTRAN and Python.

To estimate the magnitude of the associations (HRs), the effect of each SNP was modeled either as a per-allele HR (multiplicative model) or as genotype-specific HRs, and were estimated on the log-scale by maximizing the retrospective likelihood. The retrospective likelihood was fitted using the pedigree-analysis software MENDEL [17,24]. As sample sizes varied substantially between contributing centers heterogeneity was examined at the country level. All analyses were stratified by country of residence and used calendar-year and cohort-specific breast cancer incidence rates for BRCA1 [25]. Countries with small number of mutation carriers were combined with neighbouring countries to ensure sufficiently large numbers within each stratum (Table S2). USA and Canada were further stratified by reported Ashkenazi Jewish (AJ) ancestry due to large numbers of AJ carriers. In stage 3 analysis involving several countries with small numbers of mutation carriers, we assumed only 3 large strata (Europe, Australia, USA/Canada). The combined iCOGS stage and stage 3 analysis was also stratified by stage of the experiment. The analysis of associations by breast cancer ER-status was carried out by an extension of the retrospective likelihood approach to model the simultaneous effect of each SNP on more than one tumor subtype [26] (Text S1).

**Competing risk analysis.** The associations with breast and ovarian cancer risk simultaneously were assessed within a competing risk analysis framework [17] by estimating HRs simultaneously for breast and ovarian cancer risk. This analysis provides unbiased estimates of association with both diseases and more powerful tests of association in cases where an association exists between a variant and at least one of the diseases [17]. Each individual was assumed to be at risk of developing either breast or ovarian cancer, and the probabilities of developing each disease were assumed to be independent conditional on the underlying genotype. A different censoring process was used, whereby individuals were followed up to the age of the first breast or ovarian cancer diagnosis and were considered to have developed the corresponding disease. No follow-up was considered after the first cancer diagnosis. Individuals censored for breast cancer at the age of bilateral prophylactic mastectomy and for ovarian cancer at the age of RRSO were assumed to be unaffected for the corresponding disease. The remaining individuals were censored at the last observation age and were assumed to be unaffected for both diseases.

**Imputation.** For the SNP selection process, the MACH software was used to impute non-genotyped SNPs based on the phased haplotypes from HapMap Phase II (CEU, release 22). The IMPUTE2 software [27] was used to impute non-genotyped SNPs for samples genotyped on the iCOGS array (stage 1 and 2 only), based on the 1,000 Genomes haplotypes (January 2012 version). Associations between each marker and cancer risk were assessed using a similar score test to that used for the observed SNPs, but based on the posterior genotype probabilities at each imputed marker for each individual. In all analyses, we considered only SNPs with imputation information/accuracy r^2>0.30.
Absolute breast and ovarian cancer risks by combined SNP profile. We estimated the absolute risk of developing breast and ovarian cancer based on the joint distribution of all SNPs that were significantly associated with risk for BRCA1 mutation carriers based on methods previously applied to BRCA2 carriers [28]. We assumed that the average, age-specific breast and ovarian cancer incidences for BRCA1 mutation carriers, over all modifying loci, agreed with published penetrance estimates for BRCA1 [25]. The model assumed independence among the modifying loci and we used only the SNP with the strongest evidence of association from each region. We used only loci identified through the BRCA1 GWAS that exhibited associations at a genome-wide significance level, and loci that were identified through population-based GWAS of breast or ovarian cancer risk, but were also associated with those risks for BRCA1 mutation carriers. For each SNP, we used the per-allele HR and minor allele frequencies estimated from the present study. Genotype frequencies were obtained under the assumption of HWE.

Results

Samples from 11,705 BRCA1 carriers from 45 centers in 25 countries yielded high-quality data for 201,242 SNPs on the iCOGS array. The array included 31,812 BRCA1 GWAS SNPs, which were analyzed here for their associations with breast and ovarian cancer risk for BRCA1 mutation carriers (Table S2). Of the 11,705 BRCA1 mutation carriers, 2,307 samples had also been genotyped for stage 1 of the GWAS and 9,318 were unique to the stage 2 iCOGS study.

Breast cancer associations

When restricting analysis to stage 2 samples (4,681 unaffected, 4,637 affected), there was little evidence of inflation in the association test-statistic ($\lambda = 1.038$; Figure S3). Combined analysis of stage 1 and 2 samples (5,784 unaffected, 5,920 affected) revealed 66 SNPs in 28 regions with $P < 10^{-4}$ (Figure S4). These included variants from three loci (19p13, 6q25.1, 12p11) previously associated with breast cancer risk for BRCA1 mutation carriers (Table 1). Further evaluation of 18 loci associated with breast cancer susceptibility in the general population found that only the TOX3, LSP1, 2q35 and RAD51L1 loci were significantly associated with breast cancer for BRCA1 carriers (Table 1, Table S4).

After excluding SNPs from the known loci, there were 39 SNPs in 25 regions with $P = 1.2 \times 10^{-6}$–1.0 \times 10^{-4}$. Twelve of these SNPs were genotyped by iPLEX in an additional 2,646 BRCA1 carriers (1,252 unaffected, 1,394 affected, “stage 3” samples, Table S5). There was additional evidence of association with breast cancer risk for four SNPs at two loci ($P < 0.01$, Table 2). When all stages were combined, SNPs rs2290854 and rs6682208 ($r^2 = 0.84$) at 1q32, near MDM4, had combined $P$-values of association with breast cancer risk of $1.4 \times 10^{-7}$ and $4 \times 10^{-8}$, respectively. SNPs rs11196174 and rs11196173 ($r^2 = 0.96$) at 10q25.3 (in TCF7L2) had combined $P$-values of $7.5 \times 10^{-7}$ and $1.2 \times 10^{-6}$. Analysis within a competing risks framework, where associations with breast and ovarian cancer risks are evaluated simultaneously [17], revealed stronger associations with breast cancer risk for all 4 SNPs, but no associations with ovarian cancer (Table 3). In particular, we observed a genome-wide significant association between the minor allele of rs2290854 from 1q32 and breast cancer risk (per-allele HR: 1.14; 95% CI: 1.09–1.20; $P = 2.7 \times 10^{-5}$). Country-specific HR estimates for all SNPs are shown in Figure S5. Analyses stratified by BRCA1 mutation class revealed no significant evidence of a difference in the associations of any of the SNPs by the predicted functional consequences of BRCA1 mutations (Table S6). SNPs in the MDM4 and TCF7L2 loci were associated with breast cancer risk for both class1 and class2 mutation carriers.

Both the 1q32 and 10q25.3 loci were primarily associated with ER-negative breast cancer for BRCA1 (rs2290854: ER-negative HR = 1.16; 95% CI: 1.10–1.22, $P = 1.2 \times 10^{-7}$; rs11196174: HR = 1.14, 95% CI: 1.07–1.20, $P = 9.6 \times 10^{-6}$), although the differences between the ER-negative and ER-positive HRs were not significant (Table S7). Given that ER-negative breast cancers in BRCA1 and BRCA2 mutation carriers are phenotypically similar [29], we also evaluated associations between these SNPs and ER-negative breast cancer in 9,211 BRCA2 mutation carriers. While the 10q25.3 SNPs were not associated with overall or ER-negative breast cancer risk for BRCA2 carriers, the 1q32 SNPs were associated with ER-negative (rs2290854 HR = 1.16, 95% CI: 1.01–1.34; $P = 0.033$; rs6682208 HR = 1.19, 95% CI: 1.04–1.35; $P = 0.016$), but not ER-positive breast cancer (rs2290854 $P$–diff = 0.006; rs6682208 $P$–diff = 0.001). Combining the BRCA1 and BRCA2 samples provided strong evidence of association with ER-negative breast cancer (rs2290854: $P = 1.25 \times 10^{-5}$, rs6682208: $P = 2.5 \times 10^{-5}$).

The iCOGS array included additional SNPs from the 1q32 region that were not chosen based on the BRCA1 GWAS. Of these non-BRCA1 GWAS SNPs, only SNP rs4951407 was more significantly associated with risk than the BRCA1-GWAS selected SNPs ($P = 3.3 \times 10^{-6}$; HR = 1.12, 95% CI: 1.07–1.18, using stage 1 and stage 2 samples). The evidence of association with breast cancer risk was again stronger under the competing risks analysis (HR = 1.14, 95% CI: 1.08–1.20, $P = 6.1 \times 10^{-7}$). Backward multiple regression analysis, considering only the genotyped SNPs ($P < 0.01$), revealed that the most parsimonious model included only rs4951407. SNPs from the 1000 Genomes Project, were imputed for the stage 1 and stage 2 samples (Figure S6). Only imputed SNP rs12404974, located between PIK3CB and MDM4 ($r^2 = 0.77$ with rs4951407), was more significantly associated with breast cancer ($P = 2.7 \times 10^{-8}$) than any of the genotyped SNPs. None of the genotyped or imputed SNPs from 10q25.3 provided $P$-values smaller than those for rs11196174 and rs11196175 (Figure S7).

Ovarian cancer associations

Analyses of associations with ovarian cancer risk using the stage 2 samples (8,054 unaffected, 1,264 affected) revealed no evidence of inflation in the association test-statistic ($\lambda = 1.039$, Figure S3). In the combined analysis of stage 1 and 2 samples (9,866 unaffected, 1,839 affected), 62 SNPs in 17 regions were associated with ovarian cancer risk for BRCA1 carriers at $P < 10^{-4}$ (Figure S8). These included SNPs in the 9p22 and 3q25 loci previously associated with ovarian cancer risk in both the general population and BRCA1 carriers [6,7] (Table 1). Associations ($P < 0.01$) with ovarian cancer risk were also observed for SNPs in three other known ovarian cancer susceptibility loci (8q24, 17q21, 19p13), but not 2q31 (Table 1). For all loci except 9p22, SNPs were identified that displayed smaller $P$-values of association than previously published results [5–7].

After excluding SNPs from known ovarian cancer susceptibility regions, there were 48 SNPs in 15 regions with $P = 5 \times 10^{-7}$ to $10^{-4}$. Five SNPs from four of these loci were genotyped in the stage 3 samples (2,204 unaffected, 442 with ovarian cancer). Three SNPs showed additional evidence of association with ovarian cancer risk ($P < 0.02$, Table 2; Table S5). In the combined stage 1–3 analyses, SNPs rs17631303 and rs183211 ($r^2 = 0.68$) on chromosome 17q21.31 had $P$-values for association of $1 \times 10^{-8}$ and $3 \times 10^{-8}$ respectively, and rs4691139 at 4q32.3 had a $P$-value of $3.4 \times 10^{-6}$ (Table 2).

The minor alleles of rs17631303 (HR = 1.27, 95% CI: 1.17–1.38) and rs183211 (HR = 1.25, 95% CI: 1.16–1.35) at 17q21.31 were associated with increased ovarian cancer risk (Table 2). Analysis of
Table 1. Associations with breast or ovarian cancer risk for loci previously reported to be associated with cancer risk for BRCA1 mutation carriers.

<table>
<thead>
<tr>
<th>Locus</th>
<th>Previously published association in BRCA1</th>
<th>Strongest association in current set of 31,812 BRCA1 GWAS SNPs</th>
<th>Association for published SNP in set of all iCOGS SNPs</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SNP</td>
<td>all1/all2 (freq)</td>
<td>HR (95%CI)</td>
</tr>
<tr>
<td>Loci previously associated with breast cancer risk for BRCA1 carriers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1p9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6q25.1</td>
<td>rs2046210</td>
<td>C/T (0.035)</td>
<td>1.17 (1.11–1.23)</td>
</tr>
<tr>
<td>12p11</td>
<td>rs10771399</td>
<td>A/G (0.11)</td>
<td>0.87 (0.81–0.94)</td>
</tr>
<tr>
<td>19p13</td>
<td>rs8170</td>
<td>G/A (0.17)</td>
<td>1.26 (1.17–1.35)</td>
</tr>
<tr>
<td>5q31</td>
<td>rs3803662</td>
<td>C/T (0.29)</td>
<td>1.09 (1.03–1.16)</td>
</tr>
<tr>
<td>Known ovarian cancer susceptibility loci</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2q35</td>
<td>rs13387042</td>
<td>G/A (0.52)</td>
<td>1.02 (0.96–1.07)</td>
</tr>
<tr>
<td>9p22</td>
<td>rs3814113</td>
<td>T/C (0.34)</td>
<td>0.78 (0.72–0.85)</td>
</tr>
<tr>
<td>8q24</td>
<td>rs10088218</td>
<td>G/A (0.13)</td>
<td>0.89 (0.81–0.99)</td>
</tr>
<tr>
<td>3q25</td>
<td>rs3805390</td>
<td>T/C (0.075)</td>
<td>1.25 (1.10–1.42)</td>
</tr>
<tr>
<td>17q21</td>
<td>rs10303542</td>
<td>T/C (0.26)</td>
<td>1.08 (1.00–1.17)</td>
</tr>
<tr>
<td>19p13</td>
<td>rs67397200</td>
<td>C/G (0.28)</td>
<td>1.16 (1.05–1.29)</td>
</tr>
</tbody>
</table>

Freq = frequency of allele 2 in unaffected BRCA1 carriers.
HR = Per allele Hazard Ratio associated with allele 2, under a single disease risk model, unless specified.
r^2: correlation between the SNP in the present study and the published SNP.
*SNP not in BRCA1 GWAS SNP allocation on iCOGS chip.
a: rs13387042 was previously found to be associated only under the 2-df model.
b: analysis under a competing risks model.
doi:10.1371/journal.pgen.1003212.t001
Table 2. Associations with breast and ovarian cancer risk for SNPs found to be associated with risk at all 3 stages of the experiment.

<table>
<thead>
<tr>
<th>SNP, Chr, Position, Allele1/Allele2</th>
<th>Stage</th>
<th>Number</th>
<th>Allele 1 Frequency</th>
<th>HR* (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Unaffected</td>
<td>Affected</td>
<td>Unaffected</td>
</tr>
<tr>
<td>Breast Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs2290854, 1q32, 202782648, G/A</td>
<td>Stage 1</td>
<td>1104</td>
<td>1.19 (1.08–1.30)</td>
<td>1.28 (1.12–1.47)</td>
</tr>
<tr>
<td></td>
<td>Stage 2</td>
<td>4681</td>
<td>1.09 (1.03–1.16)</td>
<td>1.10 (1.02–1.19)</td>
</tr>
<tr>
<td></td>
<td>Stages1+2</td>
<td>5785</td>
<td>1.12 (1.06–1.17)</td>
<td>1.15 (1.07–1.23)</td>
</tr>
<tr>
<td></td>
<td>Stage 3</td>
<td>1252</td>
<td>1.19 (1.07–1.32)</td>
<td>1.24 (1.07–1.43)</td>
</tr>
<tr>
<td></td>
<td>Combined</td>
<td>7037</td>
<td>1.13 (1.08–1.18)</td>
<td>1.16 (1.09–1.24)</td>
</tr>
<tr>
<td>rs6682208, 1q32, 202832806, G/A</td>
<td>Stage 1</td>
<td>1104</td>
<td>1.14 (1.04–1.25)</td>
<td>1.24 (1.09–1.42)</td>
</tr>
<tr>
<td></td>
<td>Stage 2</td>
<td>4681</td>
<td>1.10 (1.04–1.17)</td>
<td>1.09 (1.01–1.19)</td>
</tr>
<tr>
<td></td>
<td>Stages1+2</td>
<td>5785</td>
<td>1.11 (1.05–1.17)</td>
<td>1.13 (1.05–1.21)</td>
</tr>
<tr>
<td></td>
<td>Stage 3</td>
<td>1250</td>
<td>1.19 (1.07–1.32)</td>
<td>1.31 (1.14–1.51)</td>
</tr>
<tr>
<td></td>
<td>Combined</td>
<td>7035</td>
<td>1.12 (1.07–1.17)</td>
<td>1.16 (1.09–1.23)</td>
</tr>
<tr>
<td>rs11196174, 10q25.3, 114724086, A/G</td>
<td>Stage 1</td>
<td>1103</td>
<td>1.15 (1.05–1.27)</td>
<td>1.17 (1.03–1.34)</td>
</tr>
<tr>
<td></td>
<td>Stage 2</td>
<td>4681</td>
<td>1.10 (1.04–1.17)</td>
<td>1.13 (1.04–1.23)</td>
</tr>
<tr>
<td></td>
<td>Stages1+2</td>
<td>5784</td>
<td>1.12 (1.06–1.18)</td>
<td>1.14 (1.06–1.23)</td>
</tr>
<tr>
<td></td>
<td>Stage 3</td>
<td>1251</td>
<td>1.16 (1.05–1.29)</td>
<td>1.08 (0.93–1.25)</td>
</tr>
<tr>
<td></td>
<td>Combined</td>
<td>7035</td>
<td>1.13 (1.07–1.18)</td>
<td>1.13 (1.06–1.21)</td>
</tr>
<tr>
<td>rs11196175, 10q25.3, 114726604, A/G</td>
<td>Stage 1</td>
<td>1101</td>
<td>1.15 (1.05–1.27)</td>
<td>1.18 (1.03–1.35)</td>
</tr>
<tr>
<td></td>
<td>Stage 2</td>
<td>4674</td>
<td>1.10 (1.03–1.17)</td>
<td>1.13 (1.04–1.22)</td>
</tr>
<tr>
<td></td>
<td>Stages1+2</td>
<td>5775</td>
<td>1.12 (1.06–1.18)</td>
<td>1.14 (1.06–1.22)</td>
</tr>
<tr>
<td></td>
<td>Stage 3</td>
<td>1251</td>
<td>1.16 (1.04–1.29)</td>
<td>1.06 (0.91–1.22)</td>
</tr>
<tr>
<td></td>
<td>Combined</td>
<td>7026</td>
<td>1.12 (1.07–1.18)</td>
<td>1.12 (1.05–1.20)</td>
</tr>
<tr>
<td>Ovarian Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs17631303, 17q21, 40872185, A/G</td>
<td>Stage 1</td>
<td>1797</td>
<td>1.46 (1.22–1.74)</td>
<td>1.36 (1.01–1.68)</td>
</tr>
<tr>
<td></td>
<td>Stage 2</td>
<td>7996</td>
<td>1.20 (1.07–1.35)</td>
<td>1.10 (0.96–1.26)</td>
</tr>
<tr>
<td></td>
<td>Stages1+2</td>
<td>9793</td>
<td>1.27 (1.16–1.40)</td>
<td>1.15 (1.03–1.29)</td>
</tr>
<tr>
<td></td>
<td>Stage 3</td>
<td>2204</td>
<td>1.27 (1.07–1.51)</td>
<td>1.24 (0.99–1.56)</td>
</tr>
<tr>
<td></td>
<td>Combined</td>
<td>11997</td>
<td>1.27 (1.17–1.38)</td>
<td>1.17 (1.06–1.29)</td>
</tr>
<tr>
<td>rs183211, 17q21, 42143493, G/A</td>
<td>Stage 1</td>
<td>1812</td>
<td>1.25 (1.06–1.48)</td>
<td>1.15 (0.92–1.44)</td>
</tr>
<tr>
<td></td>
<td>Stage 2</td>
<td>8054</td>
<td>1.25 (1.16–1.35)</td>
<td>1.16 (1.05–1.27)</td>
</tr>
<tr>
<td></td>
<td>Stages1+2</td>
<td>9866</td>
<td>1.25 (1.15–1.37)</td>
<td>1.16 (1.04–1.29)</td>
</tr>
<tr>
<td></td>
<td>Stage 3</td>
<td>2204</td>
<td>1.22 (1.04–1.39)</td>
<td>1.19 (0.91–1.54)</td>
</tr>
<tr>
<td></td>
<td>Combined</td>
<td>12070</td>
<td>1.20 (1.17–1.38)</td>
<td>1.30 (1.16–1.46)</td>
</tr>
</tbody>
</table>

*HRs estimated under the single disease risk models.
doi:10.1371/journal.pgen.1003212.002

The associations within a competing risks framework, revealed no association with breast cancer risk (Table 3). The ovarian cancer effect size was maintained in the competing risk analysis but the significance of the association was slightly weaker (P = 2 × 10^-5...
Table 3. Analysis of associations with breast and ovarian cancer risk simultaneously (competing risks analysis) for SNPs found to be associated with breast or ovarian cancer.

<table>
<thead>
<tr>
<th>SNP, Chr, Position, Allele1/Allele2 Freq</th>
<th>Breast Cancer</th>
<th>Ovarian Cancer</th>
<th>HR (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs2290854, 1q32, 202782648, G/A</td>
<td>0.31 1.08 (0.99–1.18)</td>
<td>0.31 1.08 (0.99–1.18)</td>
<td>1.08 (0.99–1.18)</td>
<td>0.08</td>
</tr>
<tr>
<td>rs6682208, 1q32, 202832806, G/A</td>
<td>0.32 1.08 (1.00–1.18)</td>
<td>0.33 1.12 (1.07–1.17)</td>
<td>1.12 (1.07–1.17)</td>
<td>0.06</td>
</tr>
<tr>
<td>rs11196174, 10q25.3, 114724086, A/G</td>
<td>0.28 1.07 (0.98–1.16)</td>
<td>0.31 1.14 (1.08–1.19)</td>
<td>1.14 (1.08–1.19)</td>
<td>0.16</td>
</tr>
<tr>
<td>rs11196175, 10q25.3, 114726604, A/G</td>
<td>0.28 1.07 (0.97–1.16)</td>
<td>0.31 1.14 (1.08–1.19)</td>
<td>1.14 (1.08–1.19)</td>
<td>0.16</td>
</tr>
<tr>
<td>rs17631303, 17q21, 40872185, A/G</td>
<td>0.19 1.26 (1.14–1.39)</td>
<td>0.19 1.26 (1.14–1.39)</td>
<td>1.26 (1.14–1.39)</td>
<td>0.10</td>
</tr>
<tr>
<td>rs183211, 17q21, 42143493, G/A</td>
<td>0.26 1.25 (1.14–1.39)</td>
<td>0.26 1.25 (1.14–1.39)</td>
<td>1.25 (1.14–1.39)</td>
<td>0.10</td>
</tr>
<tr>
<td>rs4691139, 4q32.3, 166128171, A/G</td>
<td>0.48 1.21 (1.12–1.31)</td>
<td>0.48 1.21 (1.12–1.31)</td>
<td>1.21 (1.12–1.31)</td>
<td>0.28</td>
</tr>
</tbody>
</table>

and P = 2.6 × 10^{-9} for rs17631303 and rs183211 respectively in all samples combined with larger HR estimates for the rare homozygote genotypes than those expected under a multiplicative model (Table 2).

Previous studies of the known common ovarian cancer susceptibility alleles found significant associations with ovarian cancer for both BRCA1 and BRCA2 carriers [6–7]. Thus, we evaluated the associations between the 17q21.31 SNPs and ovarian cancer risk for BRCA2 carriers using iCOGS genotype data (7300 unaffected and 651 affected). Both rs17631303 and rs183211 were associated with ovarian cancer risk for BRCA2 carriers (P = 1.98 × 10^{-4} and 9.26 × 10^{-5}, with similar magnitude and direction of association as for BRCA1 carriers. Combined analysis of BRCA1 and BRCA2 mutation carriers provided strong evidence of association (P = 2.90 × 10^{-10} and 2.01 × 10^{-9}, Table 4).

The combined analysis of stage 1 and 2 samples, and BRCA2 carriers, identified seven SNPs on the iCOGS array (pairwise r^2 range: 0.68–1.00) from a 1.3 Mb (40.8–42.1 Mb, build 36.3) region of 17q21.31 that were strongly associated (P<1.27 × 10^{-5}) with ovarian cancer risk (Table 4, Figure 2). Stepwise-regression analysis based on observed genotype data retained only one of the seven SNPs in the model, but it was not possible to distinguish between the SNPs. Imputation through the 1000 Genomes Project, revealed several SNPs in 17q21.31 with stronger associations (Figure 2, Table 4) than the most significant genotyped SNP in the combined BRCA1/2 analysis (rs169201, P = 6.24 × 10^{-11}). The most significant SNP (rs140338099 (17-44034340), P = 3 × 10^{-12}), located in MAPI, was highly correlated (r^2 = 0.78) with rs169201 in NSF (Figure 2). This locus appears to be distinct from a previously identified ovarian cancer susceptibility locus located >1 Mb distal on 17q21 (spanning 43.3–44.3 Mb, build 36.3) [30]. None of the SNPs in the novel region were strongly correlated with any of the SNPs in the 43.3–44.3 Mb region (maximum r^2 = 0.07, Figure S8). The most significantly associated SNP from the BRCA1 GWAS from the 43.3–44.3 Mb locus was rs11651753 (p = 4.6 × 10^{-6}) (Table 1) (r^2 < 0.02 with the seven most significant SNPs in the novel 17q21.31 region). An analysis of the joint associations of rs11651753 and rs17631303 from the two 17q21 loci with ovarian cancer risk for BRCA1 carriers (Stage 1 and 2 samples) revealed that both SNPs remained significant in the model (P-for inclusion = 0.001 for rs11651753, 1.2 × 10^{-6} for rs17631303), further suggesting that the two regions are independently associated with ovarian cancer for BRCA1 carriers.

The minor allele of rs4691139 at the novel 4q32.3 region was also associated with an increased ovarian cancer risk for BRCA1 carriers (per-allele HR = 1.20, 95% CI:1.17–1.38, Table 2), but was not associated with breast cancer risk (Table 3). No other SNPs from the 4q32.3 region on the iCOGS array were more significantly associated with ovarian cancer for BRCA1 carriers. Analysis of associations with variants identified through 1000 Genomes Project-based imputation of the Stage 1 and 2 samples, revealed 19 SNPs with stronger evidence of association (P = 5.4 × 10^{-7} to 1.1 × 10^{-5}) than rs4691139 (Figure S9). All were highly correlated (pairwise r^2 > 0.89) and the most significant (rs4384216) had r^2 = 0.97 with rs4691139. There was no evidence for association between rs4691139 and ovarian cancer risk for BRCA2 carriers (HR = 1.08, 95% CI: 0.96–1.21, P = 0.22).

Absolute risks of developing breast and ovarian cancer

The current analyses suggest that 10 loci are now known to be associated with breast cancer risk for BRCA1 mutation carriers: 1q32, 1q25.3, 19p13, 6q25.1, 12p11, TOX3, 2q35, LSPI and RAD51L1 all reported here and TERT [31]. Similarly, seven loci are associated with ovarian cancer risk for BRCA1 mutation
### Table 4. Associations with SNPs at the novel 17q21 region with ovarian cancer risk for BRCA1 and BRCA2 mutation carriers.

<table>
<thead>
<tr>
<th>SNP, Allele1/Allele2</th>
<th>Ovarian Cancer (Stage 1 &amp; 2 combined)</th>
<th>BRCA1 (Stage 1 &amp; 2 samples)</th>
<th>BRCA2</th>
<th>Unaffected (All2 freq)</th>
<th>BRCA1 Unaffected (All2 freq)</th>
<th>BRCA2 Unaffected (All2 freq)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR (95%CI)</td>
<td>P-trend</td>
<td>HR (95%CI)</td>
<td>P-trend</td>
<td>HR (95%CI)</td>
<td>P-trend</td>
</tr>
<tr>
<td>rs17631303, A/G</td>
<td>1.32 (1.15–1.52)</td>
<td>1.98 × 10⁻⁴</td>
<td>1.33 (1.11–1.59)</td>
<td>5.60 × 10⁻⁴</td>
<td>1.27 (1.10–1.43)</td>
<td>2.80 × 10⁻⁴</td>
</tr>
<tr>
<td>rs183211, G/A</td>
<td>1.27 (1.16–1.40)</td>
<td>3.04 × 10⁻⁴</td>
<td>1.33 (1.11–1.59)</td>
<td>5.60 × 10⁻⁴</td>
<td>1.27 (1.10–1.43)</td>
<td>2.80 × 10⁻⁴</td>
</tr>
<tr>
<td>rs169201, A/G</td>
<td>1.28 (1.14–1.44)</td>
<td>5.65 × 10⁻⁴</td>
<td>1.33 (1.11–1.59)</td>
<td>5.60 × 10⁻⁴</td>
<td>1.27 (1.10–1.43)</td>
<td>2.80 × 10⁻⁴</td>
</tr>
<tr>
<td>rs1399534, A/C</td>
<td>3.65 (2.24–5.92)</td>
<td>1.27 × 10⁻ⁱ</td>
<td>1.33 (1.11–1.59)</td>
<td>5.60 × 10⁻⁴</td>
<td>1.27 (1.10–1.43)</td>
<td>2.80 × 10⁻⁴</td>
</tr>
<tr>
<td>rs1096051, A/C</td>
<td>4.32 (1.30–13.85)</td>
<td>2.49 × 10⁻¹</td>
<td>1.33 (1.11–1.59)</td>
<td>5.60 × 10⁻⁴</td>
<td>1.27 (1.10–1.43)</td>
<td>2.80 × 10⁻⁴</td>
</tr>
<tr>
<td>rs199443, G/A</td>
<td>1.28 (1.15–1.43)</td>
<td>6.24 × 10⁻¹</td>
<td>1.33 (1.11–1.59)</td>
<td>5.60 × 10⁻⁴</td>
<td>1.27 (1.10–1.43)</td>
<td>2.80 × 10⁻⁴</td>
</tr>
<tr>
<td>rs199534, A/C</td>
<td>1.35 (1.19–1.52)</td>
<td>8.87 × 10⁻¹</td>
<td>1.33 (1.11–1.59)</td>
<td>5.60 × 10⁻⁴</td>
<td>1.27 (1.10–1.43)</td>
<td>2.80 × 10⁻⁴</td>
</tr>
</tbody>
</table>

*HRs estimated under the single disease risk model.

---

**Discussion**

In this study we analyzed data from 11,705 BRCA1 mutation carriers from CIMBA who were genotyped using the iCOGS high-density custom array, which included 31,812 SNPs selected on the basis of a BRCA1 GWAS. This study forms the large-scale replication stage of the first GWAS of breast and ovarian cancer risk modifiers for BRCA1 mutation carriers. We have identified a novel locus at 1q32, containing the MDM4 oncogene, that is associated with breast cancer risk for BRCA1 mutation carriers (P < 5 × 10⁻⁵). Although the 10q25.3 locus did not reach the strict GWAS level of significance, it showed strong evidence of association with breast cancer risk for BRCA1 carriers but did not reach a GWAS level of significance. We have also identified two novel loci associated with ovarian cancer for BRCA1 mutation carriers at 17q21.31 and 4q32.2 (P < 5 × 10⁻⁶). We further confirmed associations with loci previously shown to be associated with breast or ovarian cancer risk for BRCA1 mutation carriers. In most cases stronger associations were detected with the same SNP reported previously (due to increased sample size) or other SNPs in the regions. Future fine mapping studies of these loci will aim to identify potentially causal variants for the observed associations.
Figure 2. Mapping of the 17q21 locus. Top 3 panels: P-values of association ($-\log_{10}$ scale) with ovarian cancer risk for genotyped and imputed SNPs (1000 Genomes Project CEU), by chromosome position (b.37) at the 17q21 region, for BRCA1, BRCA2 mutation carriers and combined. Results based on the kinship-adjusted score test statistic (1 d.f.). Fourth panel: Genes in the region spanning (43.4–44.9 Mb, b.37) and the location of the most significant genotyped SNPs (in red font) and imputed SNPs (in black font). Bottom panel: Pairwise $r^2$ values for genotyped SNPs on iCOG array in the 17q21 region covering positions (43.4–44.9 Mb, b.37).

doi:10.1371/journal.pgen.1003212.g002
on stage 1 and 2 samples). This raises the possibility that variants in this locus influence breast cancer indirectly through effects on cellular metabolism.

We found that SNPs at 1q32 were primarily associated with ER-negative breast cancer risk for \textit{BRCA1} mutation carriers. There was also evidence of association with ER-negative breast cancer for \textit{BRCA2}mutation carriers. SNPs at the 1q32 region were independently selected for inclusion on iCOGS through GWAS of breast cancer in the general population by BCAC. In parallel analyses of iCOGS data by BCAC, 1q32 was found to be associated with ER-negative breast cancer [34] but not overall breast cancer risk [32]. Taken together, these results are in agreement with our findings and in line with the observation that the majority of \textit{BRCA1} breast cancers are ER-negative. However, they are not in agreement with a previous smaller candidate-gene study that found an association between a correlated SNP in \textit{MDM4} (\(r^2 = 0.85\)) and overall breast cancer risk [35]. The 1q32 locus includes the \textit{MDM4} oncogene which plays a role in regulation of p53 and MDM2 and the apoptotic response to cell stress. MDM4 is expressed in breast tissue and is amplified and overexpressed along with \textit{LRRN2} and \textit{PIK3C2B} in breast and other tumor types (TCGA) [36–38]. Although fine mapping will be necessary to identify the functionally relevant SNPs in this locus, we found evidence of cis-regulatory variation impacting \textit{MDM4} expression [39–41] (Text S1, Table S9, Figure S11), suggesting that common variation in the 1q32 locus may influence the risk of breast cancer through direct effects on \textit{MDM4} expression.

Several correlated SNPs at 17q21.31 from the iCOGS array provided strong evidence of association with ovarian cancer risk in both \textit{BRCA1} and \textit{BRCA2} mutation carriers. A subsequent analysis of these SNPs, which were selected through the \textit{BRCA1} GWAS, in case-control samples from the Ovarian Cancer Association Consortium (OCAC), revealed that the 17q21.31 locus is associated with ovarian cancer risk in the general population [Wey et al, personal communication]. Thus, 17q21.31 is likely a novel susceptibility locus for ovarian cancer in \textit{BRCA1} mutation carriers. The most significant associations at 17q21.31 were clustered in a large region of strong linkage disequilibrium which has previously been identified as a “17q21.31 inversion” (~900 kb long) consisting of two haplotypes (termed H1 and H2) [42]. The minor allele of rs2532348 (MAF = 0.21), which tags H2, was associated with increased ovarian cancer risk for \textit{BRCA1} mutation carriers (Table 4). The 1.3 Mb 17q21.31 locus contains 13 genes and several predicted pseudogenes (Figure 2), several of which are

---

**Figure 3. Predicted breast and ovarian cancer absolute risks for \textit{BRCA1} mutation carriers at the 5th, 10th, 90th, and 95th percentiles of the combined SNP profile distributions.** The minimum, maximum and average risks are also shown. Predicted cancer risks are based on the associations of known breast or ovarian cancer susceptibility loci (identified through GWAS) with cancer risk for \textit{BRCA1} mutation carriers and loci identified through the present study. Breast cancer risks based on the associations with: 1q32, 10q25.3, 19p13, 6q25.1, 12p11, TOX3, 2q35, LSP1, RAD51L1 (based on HR and minor allele frequency estimates from Table 1, Table 2, and Table S4) and TERT [31]. Ovarian cancer risks based on the associations with: 9p22, 8q24, 3q25, 17q21, 19p13 (Table 1) and 17q21.31, 4q32.3 (Table 2). Only the top SNP from each region was chosen. Average breast and ovarian cancer risks were obtained from published data [25]. The methods for calculating the predicted risks have been described previously [28].

doi:10.1371/journal.pgen.1003212.g003
expressed in normal ovarian surface epithelium and ovarian adenocarcinoma [43]. Variation in this region has been associated with Parkinson’s disease (MAPT, PLEKH1, NSF, c17orf69), progressive supranuclear palsy (MAPT), celiac disease (WNT3), bone mineral density (CHRNA1) (NHGRI GWAS catalog) and intracranial volume [44]. Of the top hits for these phenotypes, SNP rs199553 in NSF, previously associated with Parkinson’s disease [43] and rs9915347 associated with intracranial volume [44] were strongly associated with ovarian cancer (P<10^-8 in BRCA1/2 combined). Whether these phenotypes have shared causal variants in this locus remains to be elucidated. Further exploration of the functional relevance of the strongest hits in the 17q21.31 locus (Pcausal variants in this locus remains to be elucidated. Further exploration of the functional relevance of the strongest hits in the 17q21.31 locus (P<10^-8 in BRCA1/2 combined) provided evidence that cis-regulatory variation alters expression of several genes at 17q21, including PLEKH1, c17orf69, ARHGAP27, MAPT, KANSL1 and WNT3 [39,41] (Table S9, Figure S12), suggesting that ovarian cancer risk may be associated with altered expression of one or more genes in this region.

Our analyses revealed that a second novel locus at 4q32.2 was also associated with ovarian cancer risk for BRCA1 mutation carriers (P<5x10^-6). However, we found no evidence of association for these SNPs with ovarian cancer risk for BRCA2 mutation carriers using 8,211 CIMBA samples genotyped using the iCOGS array. Likewise, no evidence of association was found between rs4691139 at 4q32.3 and ovarian cancer risk in the general population based on data by OCAC data derived from 18,174 cases and 26,134 controls (odds ratio = 1.00, 95%CI:0.97–1.04, P = 0.76) [46]. The confidence intervals rule out a comparable effect to that found in BRCA1 carriers. Therefore, our findings may represent a BRCA1-specific association with ovarian cancer risk, the first of its kind. The 4q32.2 region contains several genes expressed in normal ovarian epithelium and ovarian tumors (TCGA).

In summary, we have identified a novel locus at 1q32 associated with breast cancer risk for BRCA1 mutation carriers, which was also associated with ER-negative breast cancer for BRCA2 carriers and in the general population. A separate locus at 10q23.5 provided strong evidence of association with breast cancer risk for BRCA1 carriers. We have also identified 2 novel loci associated with ovarian cancer for BRCA1 mutation carriers. Of these, the 4q32.2 locus was associated with ovarian cancer risk for BRCA1 carriers but not for BRCA2 carriers or in the general population. Additional functional characterisation of the loci will further improve our understanding of the biology of breast and ovarian cancer development in BRCA1 carriers. Taken together with other identified genetic modifiers, 10 loci are now known to be associated with breast cancer risk for BRCA1 mutation carriers (1q32, 10q25.3, 19p13, 6q25.1, 12p11, TOX3, 2q35, LSP1, RAD51L1 and TERT) and seven loci are known to be associated with ovarian cancer risk for BRCA1 mutation carriers (9p22, 8q24, 3q25, 17q21, 19p13 and 17q21.3, 4q32.3).

As BRCA1 mutations confer high breast and ovarian cancer risks, the results from the present study, taken together with other identified genetic modifiers, demonstrate for the first time that they can result in large differences in the absolute risk of developing breast or ovarian cancer for BRCA1 between genotypes. For example, the breast cancer lifetime risks for the 5% of BRCA1 carriers at lowest risk are predicted to be 28–50% compared to 81–100% for the 5% at highest risk (Figure 3). Based on the distribution of ovarian cancer risk modifiers, the 5% of BRCA1 mutation carriers at lowest risk will have a lifetime risk of developing ovarian cancer of 28% or lower whereas the 5% at highest risk will have a lifetime risk of 63% or higher. Similarly, the breast cancer risk by age 40 is predicted to be 4–9% for the 5% of BRCA1 carriers at lowest risk compared to 20–49% for the 5% at highest risk, whereas the ovarian cancer risk at age 50 ranges from 3–7% for the 5% at lowest risk and from 18–47% for the 5% at highest risk. The risks at all ages for the 10% at highest or lowest risk of breast and ovarian cancer are predicted to be similar to those for the highest and lowest 5%. Thus, at least 20% of BRCA1 mutation carriers are predicted to have absolute risks of disease that are different from the average BRCA1 carriers. These large differences in cancer risks may have practical implications for the clinical management of BRCA1 mutation carriers, for example in deciding the timing of interventions. Such risks, in combination with other lifestyle and hormonal risk factors could be incorporated into cancer risk prediction algorithms for use by clinical genetics centers. These algorithms could then be used to inform the development of effective and consistent clinical recommendations for the clinical management of BRCA1 mutation carriers.

Supporting Information

Figure S1  Multidimensional scaling of stage 1 and stage 2 (genotyped on iCOGS) samples. Panel A: Graphical representation of the first two components, for the BRCA1 carriers, for subgroups defined by the common 185deiAG (c68_69delAG) BRCA1 Jewish founder mutation, the 5382insC (c.5266dupC) Eastern European founder mutation and Hapap individuals (CEU: European; ASI: Includes CHB and JPT populations; YRI: African). Panel B: Red dots represent the samples with >22% non-European ancestry, excluded from the analysis. (PDF)

Figure S2  Genotyping cluster plots in the BRCA1 samples for the key associated SNPs. (PDF)

Figure S3  Quantile-quantile plot for the kinship adjusted score test statistic for stage 2 samples (1 degree of freedom χ2 trend test) for the associations with breast cancer (panel A) and ovarian cancer (panel B) risk for BRCA1 mutation carriers. The y=x line corresponds to the expected distribution, under the hypothesis of no inflation. Inflation was estimated using the values of the lowest 90% test statistics. (PDF)

Figure S4  P-values (on –log10 scale) by chromosomal position, for the associations of 31,812 BRCA1 GWAS SNPs with breast (panel A) and ovarian (panel B) cancer risk for BRCA1 mutation carriers in the combined stage 1 and stage 2 samples. Blue lines correspond to a P-value of 10^-5; red lines correspond to P-value 5x10^-10. (PDF)

Figure S5  Forest plots of the associations by country of residence of BRCA1 mutation carriers in the combined stage 1, stage 2 and stage 3 samples for SNPs found to be associated with breast and ovarian cancer risk for BRCA1 mutation carriers. Squares indicate the country specific, per-allele HR estimates for the SNPs. The area of the square is proportional to the inverse of the variance of the estimate. Horizontal lines indicate 95% confidence intervals. There was some evidence of heterogeneity in country-specific HR estimates for rs2290854 and rs6682208 SNP (P = 0.04 and 0.02 respectively, Figure S3), but after accounting for opposite effects of these SNPs in Finland/Denmark, there was no evidence of heterogeneity. There was some evidence of heterogeneity in the country-specific HRs for rs17631303 (P-het = 0.004, df= 19) but this was no longer present after excluding one country (Poland, P-
heterogeneity in the study country-specific HRs for any of the other SNPs (P > 0.68).

**Figure S6** MDM4 regional association plot using BRCA1 stage 1 and stage 2 samples. P-values for association (−log_{10} scale) with breast cancer risk for BRCA1 mutation carriers for genotyped SNPs (diamond symbols △) and SNPs imputed from the 1000 genomes project data (square symbols □), by position (hg18) on chromosome 1. Red gradient represents r^2 value with the most significant genotyped SNP rs4951407. The blue peaks represent recombination rate in the region.

(PDF)

**Figure S7** TCF7L2 regional association plot using BRCA1 stage 1 and stage 2 samples. P-values for association (−log_{10} scale) with breast cancer risk for BRCA1 mutation carriers for genotyped SNPs (diamond symbols △) and SNPs imputed from the 1000 genomes project data (square symbols □), by position (hg18) on chromosome 1. Missing genotypes were replaced by imputed results. Red gradient represents r^2 value with the most significant genotyped SNP rs11196174. The blue peaks represent recombination rate in the region.

(PDF)

**Figure S8** Linkage disequilibrium patterns between the SNPs in the novel (17q21.31) and previously identified regions on 17q21. SNPs in the novel region are uncorrelated with SNPs in the 43.3–44.3 Mb region (positions according to hg build 36.3).

(PDF)

**Figure S9** 4q32.3 regional association plot using BRCA1 stage 1 and stage 2 samples. P-values for association (−log_{10} scale) with ovarian cancer risk for BRCA1 mutation carriers for genotyped SNPs (diamond symbols △) and imputed SNPs from the 1000 genomes project data (square symbols □), by position (hg18) on chromosome 1. Missing genotypes were replaced by imputed results. Red gradient represents r^2 value with the most significant genotyped SNP rs4691139. Blue peaks represent recombination rate in the region.

(PDF)

**Figure S10** Combined Hazard Ratios (HR) for breast and ovarian cancer for BRCA1 mutation carriers. (A) HR for Breast Cancer based on 10 loci associated with breast cancer risk for BRCA1 mutation carriers. (B) Ovarian Cancer based on 7 loci associated with ovarian cancer risk for BRCA1 mutation carriers. All HRs computed relative to the lowest risk category. The Y-axes translate the combined HRs into absolute risks of developing breast or ovarian cancer by age 80. The absolute risks and HRs at different percentiles of the combined genotype distribution are also marked. The combined HRs were obtained under the assumption that the loci interact multiplicatively.

(PDF)

**Figure S11** Cis-eQTL and allelic expression (AE) analyses at MDM4 locus. A) Cis-eQTLs for SNPs at MDM4 locus using expression data from primary human osteoblasts (HOb). B) AE mapping for cis-regulatory variation in MDM4 locus using primary skin fibroblasts. Coordinates (hg18) for locus shown on top; blue tracks indicate the −log_{10}(P value) of the association across all SNPs tested. The location of transcripts in this region is shown below.

(PDF)

**Figure S12** Cis-eQTL and allelic expression (AE) analyses at chr17q21.31 locus. (Upper panel) Cis-eQTLs for SNPs at chr17q21.31 locus using expression data from primary human osteoblasts. Allelic expression mapping for cis-regulatory variation in KANSL1 (middle panel) and WNT3 loci (lower panel) using a CEL population panel of lymphoblastoid cells. Coordinates (hg18) for loci are shown on top; blue tracks indicate the −log_{10}(P value) of the association across all SNPs tested. The location of transcripts in these regions is shown.

(PDF)

**Table S1** Affected and unaffected BRCA1 mutation carriers by study country in the breast and ovarian cancer analysis used in SNP selection for the iCOGS array.

(DOCX)

**Table S2** Origin of BRCA1 samples by Country and Stage used in the current analysis.

(DOCX)

**Table S3** Sample and SNP quality control summary.

(DOCX)

**Table S4** Associations with breast cancer risk for BRCA1 mutation carriers, for known breast cancer susceptibility variants.

(DOCX)

**Table S5** Associations with BRCA1 breast or ovarian cancer risk for SNPs genotyped at stages 1, 2, and 3.

(DOCX)

**Table S6** Analysis of breast cancer associations by BRCA1 mutation class.

(DOCX)

**Table S7** Associations with Breast Cancer ER status in BRCA1 carriers for SNPs genotyped in stages 1–3.

(DOCX)

**Table S8** Imputed SNPs at the novel 17q21 region with P-values less than the most significant genotyped SNP rs169201.

(DOCX)

**Table S9** SNPs associated (P < 1 × 10^{-5}) with local expression and Allelic Imbalance.

(DOCX)

**Text S1** Supplementary Methods.

(DOCX)

**Acknowledgments**

Antonis C. Antoniou is a Cancer Research–UK Senior Cancer Research Fellow. Douglas F. Easton is a Cancer Research UK Principal Research Fellow. Georgia Chenevix-Trench is an NHMRC Senior Principal Research Fellow.

**iCOGS:** CIMBA acknowledges the contributions of Kyriaki Michailidou, Jonathan Tyrer, and Ali Amin Al Olama to the iCOGS statistical analyses; Shalhina Ahmed, Melanie J. Maranian, and Catherine S. Healey for their contributions to the iCOGS genotyping quality control process; and the staff of the genotyping unit in the Medical Genomics Facility at the Mayo Clinic under the supervision of Dr. Julie Cunningham.

**Breast Cancer Family Registry (BCFR) Studies:** Samples from the NG-BCFR were processed and distributed by the Coriell Institute for Medical Research. We wish to thank members and participants in the Breast Cancer Family Registry for their contributions to the study. The ABCFS would like to also thank Maggie Angelakos, Judi Maskiell, and Gillian Dice. The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR.
Novel Modifiers of BRCA1 Cancer Risk


BRCA-1 / BRCA-2 gene mutations and breast cancer in South African women (BMBSA): BMBSA thanks the families who contributed to the BMBSA study.

Beckman Research Institute of the City of Hope (BRICOH): BRICOH thanks Greg Wilhoite and Marie Pinto for their work in participant enrollment and biospecimen and data management.

Copenhagen Breast Cancer Study (CBCS): CBCS thanks the Danish Breast Cancer Cooperative Group (DBCG) for their clinical data.

Spanish National Cancer Centre (CNIO): CNIO thanks Alicia Barroso, Rosario Alonso and Guillermo Pita for their assistance.

Consorzio Studi Italiani sui Tumori Erediattari Alla Mamma (CONSIT 1-4M): CONSIT 1-4M acknowledges Dr. D. Zaffaroni of the Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Monica Barile of Istituto Europeo di Oncologia (IEO), Milan, Riccardo Dolletti of the Centro di Riferimento Oncologico (CRO) IRCCS, Aviano (PN), Maurizio Genuardi of University of Florence, Florence, Giuseppe Giannini of “La Sapienza” University, Rome, Adele Patrini of the Ospedale di Circolo-Università dell’Insubria, Varese, Antonella Savarese and Aline Martayain of the Istituto Nazionale Tumori Research Centre and Stefania Tommasi of the Istituto Nazionale Tumori “Giovanni Paolo II”, Bari and the personnel of the CGT-lab at IFOM-IEO Campus, Milan, Italy.

Dana-Farber Cancer Institute (DFCI): DFCI thanks the study staff and participants.

The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON): HEBON recognizes Netherlands Cancer Institute (NKI), M.A. Roos-Kroes, G.R. van den Bent, F.E. van Leeuwen, M.K. Schmidt, J. de Lange; Erasmus Medical Center, Rotterdam, NL; J.M. Collée, A.M.W. van den Ouweland, M.J. Hooging, C. Scynaee; Leiden University Medical Center, NL; C.J. van Aperen, J.T. Wijnen, R.A. Tollenaar, P. Devliee, T.C.T.E.F. van Cronenborg; Radboud University Nijmegen Medical Center, NL; C.M. Kets, A.R. Mensenkamp; University Medical Center Utrecht, NL; M.G.E.M. Assens, R.B. van der Luijt; University Medical Center Utrecht, NL; J.J.P. Gille, Q. Waisfisz, H.E.J. Meijers-Heijboer; University Hospital Maastricht, NL; E.B. Gomez-Garcia, M.J. Blok; University Medical Center Groningen, NL; J.C. Oosterwiëk, H. van der Hout, M.J. Mourits, G.H. de Bock.


Fox Agnes Cancer Centre (FACC): FACC thanks Dr. Betsy Bove for her technical support.

German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC): GC-HBOC thanks all family members who participated in this study, Wolfram Heinrichz, Center Leipzig, and Dieter Schäfer, Center Frankfurt, for providing DNA samples and Juliane Köhler for excellent technical assistance.


GAST: G-FAST acknowledges the contribution of Bruce Poppe and Anne De Paepe and the technical support of Isse Coene en Brecht Crombeez.

Hospital Clinico San Carlos (HCSC): HCSC acknowledges Alicia Tosar for her technical assistance.

Helsinki Breast Cancer Study (HEBCS): HEBCS thanks Carl Blomquist, Kirsti Aalonen and IRJ Kerkka for their help with the Helsinki breast cancer data and samples.

Study of Genetic Mutations in Breast and Ovarian Cancer patients in Hong Kong and Asia (HRBCP): HRBCP thanks Hong Kong Sanatorium and Hospital for their continual support.

Molecular Genetic Studies of Breast and Ovarian Cancer in Hungary (HUNBOCS): HUNBOCS thanks Hungarian Breast and Ovarian Cancer Study Group members James Papp, Aniko Bozik, Kristof
Arvai, Judith Franko, Maria Balogh, Gabriella Varga, Judith Ferenczi, Department of Molecular Genetics, National Institute of Oncology, Budapest, Hungary) and the clinicians and patients for their contributions to this study.

The interdisciplinary Health Research Internal Team Breast Cancer Susceptibility INHERIT) INHERIT thanks Dr. Martine Dumont, Martine Tranchant for sample management and skilled technical assistance. J.S. is Chairholder of the Canada Research Chair in Oncogenetics.

Kathleen Cunningham Consortium for Research into Familial Breast Cancer (kConFab): kConFab thanks Heather Thorne, Eveline Niedermayer, all the kConFab research nurses and staff, the heads and staff of the Family Cancer Clinics, and the Clinical Follow Up Study for their contributions to this resource, and the many families who contribute to kConFab.

ModSQUAD Study of Quantitative Effects on Disease (MODSQUAD): MODSQUAD acknowledges ModSQuaD members Csilla Szabo and Zohra Ali-Kahn Catts (University of Delaware, Newark, USA); Lenka Forcova and Eva Machackova (Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno, Czech Republic); and Michal Zikan, Petr Polhriek and Zdenek Klebl (Oncogynecologic Center and Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic).

National Israeli Cancer Control Center (NICCC): NICCC thanks the NICCC National Familial Cancer Consultation Service team led by Sara Dishon, the laboratory team led by Dr. Flavio Lejkowicz, and the research field operations team led by Dr. Mila Pinchev.

Ontario Cancer Genetics Network (OGCN): OCGN thanks the study staff and participants.

The Ohio State University Comprehensive Cancer Center (OSUCCC): OSU CCG acknowledges Kevin Sweet, Caroline Craven and Michelle O’Connor who were instrumental in accrual of study participants, ascertainment of medical records and database management. Samples were processed by the OSU Human Genetics Sample Bank.

South East Asian Breast Cancer Association Study (SEABASS): SEABASS thanks Yip Cheng Har, Nur Aishah Mohd Taib, Phuah Sze Yee, Norhashimah Hassan and all the research nurses, research assistants and doctors involved in the MyBRaC Study for assistance in patient recruitment, data collection and sample preparation. In addition, we thank Philip Iau, Sng Jen-Hwei and Sharifah Nor Aziah for contributing samples from the Singapore Breast Cancer Study and the HUKM-HKI Study respectively.

Sheba Medical Centre (SMC): SMC acknowledges the assistance of the Sheba Comprehensive breast cancer center team at the Sheba Medical Centre for assistance in this study.

Swedish Breast Cancer Study (SWE-BRCA): SWE-BRCA acknowledges SWE-BRCA collaborators from Lund University and University Hospital: Åke Borg, Håkan Olsson, Helena Jerström, Karin Henriksson, Katja Harbst, Maria Soller, Niklas Loman, Ulf Kristoffersson; Gothenburg Sahlgrenska University Hospital: Anna Överholm, Margareta Nordling, Per Karlsson, Zakaryn Emberti. Stockholm and Karolinska University Hospital: Anna von Wachenfeldt, Annelie Liljegren, Annika Lindblom, Brita Arver, Gisela Barbany Bastinza, Johanna Rantala; Umeå University Hospital: Beatrice Melin, Christine Edvinsdotter Arndor, Monica Eeman-Andersson; Uppsala University: Hans Ehrenström, Maritta Hellström Pigg, Richard Rosenquist; Linköping University Hospital: Marie Stenmark-Aksamal, Sigurn Eiguren.

The University of Chicago Center for Clinical Cancer Research (UCCCC): UCCHCGO thanks Cecilia Zvosec, Qun Niu, physicians, genetic counselors, research nurses and staff of the Cancer Risk Clinic for their contributions to this resource, and the many families who contribute to our program. OIO is an ACS Clinical Research Professor.

University of California Los Angeles (UCLA): UCLA thanks Joyce Seldon MSGC and Lorna Kwan, MPH for assembling the data for this study.

University of California San Francisco (UCSF): UCSF thanks Ms. Salina Chan for her data management and the following genetic counselors for participant recruitment: Beth Crawford, Nicola Stewart, Julie Mak, and Kate Lamvik.

United Kingdom Familial Ovarian Cancer Registries (UKFOCR): UKFOCR thanks Paul Pharoah, Simon Gayther, Carole Pye, Patricia Harrington and Eva Wozniak for their contributions towards the UKFOCR.

Victorian Familial Cancer Trials Group (VFCTG): VFCTG thanks Sarah Sawyer and Rebecca Driessen for assembling this data and Ella Thompson for performing all DNA amplification.

Author Contributions


